This is a review article summarizing existing research on the role of the PI3K-AKT-mTOR signaling pathway in renal cell carcinoma (RCC). The review does not present new primary data, and details on study design, population, sample size, and specific interventions are not reported. The text describes associations and dysregulation of the pathway with tumor progression, not causation from an intervention.
The main finding is that the PI3K-AKT-mTOR pathway is often abnormally activated in RCC and is associated with tumor progression and poor prognosis. The review notes that small-molecule inhibitors targeting this pathway have shown potential in preclinical studies and early-phase clinical trials. However, it states these inhibitors face clinical challenges. The review proposes combination therapy strategies, including with natural products, as a new approach.
Safety and tolerability data for any specific agents are not reported. Key limitations stem from the nature of the article as a review summarizing other research; it does not provide new efficacy or safety outcomes. The practice relevance is restrained: findings regarding inhibitors are based on preclinical and early-phase data, and proposed combination strategies are not yet established in clinical practice. The review highlights a biological pathway of interest but does not support specific clinical applications.
A recent review article looked at existing research on a cell communication system called the PI3K-AKT-mTOR pathway in kidney cancer, specifically renal cell carcinoma (RCC). The article summarized what other studies have found, rather than reporting new patient data. It explained that this pathway is frequently overactive in RCC tumors, and this overactivity is associated with the cancer growing and spreading, as well as with poorer patient outcomes.
The review discussed that drugs designed to block this pathway, called small-molecule inhibitors, have shown promise in laboratory studies and very early human trials. It also mentioned the idea of combining these drugs with other treatments, including some natural products, as a potential future strategy. However, the article did not report on any specific new clinical trial results, patient numbers, or safety data from these approaches.
It is important to understand that this is a review of existing literature, not a new clinical study. The potential treatments it discusses are still in the research phase. The article itself notes that turning these laboratory findings into reliable, effective treatments for patients faces significant clinical challenges. Readers should view this as a summary of ongoing scientific exploration into a complex cancer, not as a report on a ready-to-use new therapy.
What this means for you: Early research explores a kidney cancer pathway, but treatments based on it are not yet proven or available.
View Original Abstract ↓
Renal cell carcinoma (RCC) is a type of solid tumor with one of the highest incidences among urinary system malignancies, and its incidence continues to increase worldwide. The PI3K-AKT-mTOR signaling pathway, as a central signaling hub that regulates biological processes such as cell survival, proliferation, metabolism, and metastasis, often exhibits abnormal and sustained activation during the pathological progression of RCC. Dysregulation of this pathway synergistically promotes tumor progression through multiple mechanisms, including enhancing the survival and clonal expansion of tumor cells, inducing angiogenesis, driving metabolic reprogramming of the tumor microenvironment, and mediating treatment resistance. These pathological changes are closely associated with poor patient prognosis. Given the central role of the PI3K-AKT-mTOR signaling pathway in the pathogenesis of RCC, it has become a key target for targeted therapeutic intervention. Although multiple small-molecule inhibitors targeting this pathway have demonstrated potential for inhibiting tumor growth in preclinical studies and early-phase clinical trials, their clinical application still faces numerous challenges. Against this backdrop, combination therapy strategies offer a new approach to overcome the limitations of single-agent therapy, not only enhancing treatment efficacy but also potentially reducing the risk of drug resistance. Notably, natural products and their derivatives, due to their low toxicity, ability to modulate multiple targets, and specific inhibitory effects on cancer stem cells, are regarded as promising sensitizers in combination therapy. This article systematically reviews the pathological features of RCC and current clinical treatment strategies, with a focus on exploring the molecular regulatory mechanisms of the PI3K-AKT-mTOR signaling pathway in tumor progression, while highlighting the latest research advances in small-molecule inhibitors targeting this pathway. Integrating preclinical mechanistic studies and relevant clinical trial data, the limitations of existing agents are analyzed, and potential optimization directions are proposed, aiming to provide theoretical support and practical references for the clinical translation of precision therapy for RCC and to promote the transformation of pathway-based combination therapy models into clinical applications.
